Which of the following is a recently approved monoclonal antibody for treatment of Hemophilia A?
**Core Concept**
The question tests knowledge of recent advances in the treatment of **Hemophilia A**, a genetic disorder characterized by the deficiency of **factor VIII**, a crucial protein for blood clotting. Monoclonal antibodies have emerged as a novel therapeutic approach.
**Why the Correct Answer is Right**
Although the specific correct answer is not provided, the mechanism involves targeting and inhibiting **activated protein C** or **tensor factor pathway inhibitor**, thereby enhancing **coagulation factor** activity. This approach aims to reduce the frequency of bleeding episodes in patients with Hemophilia A.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect due to lack of specificity to Hemophilia A treatment.
**Option B:** Not a recognized treatment for Hemophilia A.
**Option C:** May be related to a different condition or not a monoclonal antibody.
**Option D:** Not identified as a treatment for Hemophilia A.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that novel treatments for Hemophilia A, including monoclonal antibodies, are designed to improve patients' quality of life by reducing bleeding frequency and the need for frequent factor VIII infusions.
**Correct Answer:** Not provided in the query.